We found high quality evidence that hormone therapy in both primary and secondary prevention conferred no protective effects for all-cause mortality , cardiovascular death , non-fatal myocardial infa rct ion , angina , or revascularisation .
There was no strong evidence of effect on risk of stroke in this group .
Our review findings provide strong evidence that treatment with hormone therapy in post-menopausal women overall , for either primary or secondary prevention of cardiovascular disease events has little if any benefit and causes an increase in the risk of stroke and venous thromboembolic events
BACKGROUND Evidence from systematic review s of observational studies suggests that hormone therapy may have beneficial effects in reducing the incidence of cardiovascular disease events in post-menopausal women , however the results of r and omised controlled trials ( RCTs ) have had mixed results .
This is an up date d version of a Cochrane review published in 2013 .
OBJECTIVES To assess the effects of hormone therapy for the prevention of cardiovascular disease in post-menopausal women , and whether there are differential effects between use in primary or secondary prevention .
Secondary aims were to undertake exploratory analyses to ( i ) assess the impact of time since menopause that treatment was commenced ( ≥ 10 years versus < 10 years ) , and where these data were not available , use age of trial participants at baseline as a proxy ( ≥ 60 years of age versus < 60 years of age ) ; and ( ii ) assess the effects of length of time on treatment .
Does vitamin D3 have negative effects on serum levels of lipids? A follow-up study with a sequential combination of estradiol valerate and cyproterone acetate and/or vitamin D3.
The effects of four different treatment schedules on serum lipid concentrations were studied for 1 year in 402 postmenopausal women in the Kuopio Osteoporosis Study . The women were r and omized to four treatment groups : A , Sequential combination of estradiol valerate and cyproterone acetate ( Climen ) ; B , Vitamin D3 , 300 IU/day ; C , Climen+Vitamin D3 , D , placebo . In group A , serum concentrations of total cholesterol ( Chol ) decreased by 4.8 % in 6 months and by 6.2 % in 12 months ( P < 0.001 ) , but in group C the decrease was only 2.9 % in 6 months ( P < 0.05 ) and 3.4 % in 12 months ( P < 0.01 ) . The decline of total-Chol in group A was accounted for by the 6.8 % to 7.5 % decrease in LDL-Chol levels ( P < 0.001 ) . The decrease of LDL-Chol in group C was statistically non-significant . Use of vitamin D3 ( group B ) , increased serum Chol by 2.7 % ( 6 months ) , P < 0.05 and by 2.1 % ( 12 months ) and the increases were the result of the 6.0 % to 6.2 % increase in LDL-Chol levels in 6 and 12 months , respectively ( P < 0.001 ) . Serum concentrations of HDL-Chol and TG remained relatively stable in all groups . No correlations were found between LDL-Chol , 25-OH-D3 and 1,25(OH)2-D3 levels in group B. Our results confirm the beneficial effect of estradiol valerate and cyproterone acetate on the lipid profile . In contrast , vitamin D3 had a negative influence on this profile by increasing serum concentrations of LDL-Chol . ( ABSTRACT TRUNCATED AT 250 WORDS
We found high quality evidence that hormone therapy in both primary and secondary prevention conferred no protective effects for all-cause mortality , cardiovascular death , non-fatal myocardial infa rct ion , angina , or revascularisation .
There was no strong evidence of effect on risk of stroke in this group .
Our review findings provide strong evidence that treatment with hormone therapy in post-menopausal women overall , for either primary or secondary prevention of cardiovascular disease events has little if any benefit and causes an increase in the risk of stroke and venous thromboembolic events
BACKGROUND Evidence from systematic review s of observational studies suggests that hormone therapy may have beneficial effects in reducing the incidence of cardiovascular disease events in post-menopausal women , however the results of r and omised controlled trials ( RCTs ) have had mixed results .
This is an up date d version of a Cochrane review published in 2013 .
OBJECTIVES To assess the effects of hormone therapy for the prevention of cardiovascular disease in post-menopausal women , and whether there are differential effects between use in primary or secondary prevention .
Secondary aims were to undertake exploratory analyses to ( i ) assess the impact of time since menopause that treatment was commenced ( ≥ 10 years versus < 10 years ) , and where these data were not available , use age of trial participants at baseline as a proxy ( ≥ 60 years of age versus < 60 years of age ) ; and ( ii ) assess the effects of length of time on treatment .